Description: Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
Home Page: www.allakos.com
ALLK Technical Analysis
975 Island Drive
Redwood City,
CA
94065
United States
Phone:
650 597 5002
Officers
| Name | Title |
|---|---|
| Dr. Robert Alexander Ph.D. | CEO & Director |
| Dr. Adam L. Tomasi Ph.D. | Pres & COO |
| Mr. Baird Radford III | Chief Financial Officer |
| Dr. Henrik Sandvad Rasmussen | Strategic Advisor |
| Dr. Craig Paterson M.D. | Chief Medical Officer |
| Brad Youngblood | Head of Research |
| Mr. Alan Chang | Director of Medical Affairs & Data Analytics |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8517 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-07-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 192 |